Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Profit After Tax (2018 - 2025)

Historic Profit After Tax for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$6.5 million.

  • Inmune Bio's Profit After Tax rose 4648.14% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.9 million, marking a year-over-year decrease of 2091.73%. This contributed to the annual value of -$42.1 million for FY2024, which is 4029.59% down from last year.
  • Latest data reveals that Inmune Bio reported Profit After Tax of -$6.5 million as of Q3 2025, which was up 4648.14% from -$24.5 million recorded in Q2 2025.
  • Inmune Bio's 5-year Profit After Tax high stood at -$4.6 million for Q1 2021, and its period low was -$24.5 million during Q2 2025.
  • In the last 5 years, Inmune Bio's Profit After Tax had a median value of -$8.4 million in 2023 and averaged -$9.0 million.
  • The largest annual percentage gain for Inmune Bio's Profit After Tax in the last 5 years was 4648.14% (2025), contrasted with its biggest fall of 15095.42% (2025).
  • Inmune Bio's Profit After Tax (Quarter) stood at -$9.7 million in 2021, then surged by 39.69% to -$5.8 million in 2022, then tumbled by 44.15% to -$8.4 million in 2023, then fell by 9.85% to -$9.2 million in 2024, then increased by 29.93% to -$6.5 million in 2025.
  • Its last three reported values are -$6.5 million in Q3 2025, -$24.5 million for Q2 2025, and -$9.7 million during Q1 2025.